Detalles de la búsqueda
1.
Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
Future Oncol
; 19(26): 1769-1776, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439181
2.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33684370
3.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Lancet Oncol
; 21(9): 1173-1187, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758455
4.
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
Radiother Oncol
; 197: 110329, 2024 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38768714
5.
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Lancet Healthy Longev
; 5(6): e392-e405, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38759667
6.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Lancet Healthy Longev
; 5(3): e182-e193, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38432247
7.
[French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment]. / Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures Principes généraux de traitement.
Bull Cancer
; 111(4): 393-415, 2024 Apr.
Artículo
en Francés
| MEDLINE | ID: mdl-38418334
8.
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Lancet Oncol
; 13(2): 145-53, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22261362
9.
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).
Eur J Cancer
; 178: 114-127, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36434888
10.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Eur J Cancer
; 183: 24-37, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796234
11.
A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.
Am J Clin Nutr
; 112(6): 1523-1531, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32936874
12.
Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
Eur J Cancer
; 133: 86-93, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32454417
13.
Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer.
Patient Prefer Adherence
; 14: 859-868, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32546980
14.
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Eur J Cancer
; 141: 21-29, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125944
15.
[National standard for the treatment of squamous cell carcinoma of upper aerodigestive tract]. / Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures.
Bull Cancer
; 111(4): 327-332, 2024 Apr.
Artículo
en Francés
| MEDLINE | ID: mdl-38336530
16.
Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
J Clin Oncol
; 36(31): 3077-3083, 2018 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30016178
17.
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
J Clin Oncol
; : JCO2017762518, 2018 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29878867
18.
Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.
Int J Radiat Oncol Biol Phys
; 99(3): 590-595, 2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29280453
19.
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Oral Oncol
; 71: 61-66, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28688693
20.
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
J Natl Cancer Inst
; 108(4)2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26681800